Adjunctive therapies in type 1 diabetes: What, when and for whom?

Adjunctive therapies in type 1 diabetes: What, when and for whom?

Adjunctive therapies in type 1 diabetes: What, when and for whom? (149953)

Jennifer Snaith ¹

Department of Diabetes and Endocrinology, Westmead Hospital, Westmead, NSW, Australia

People living with type 1 diabetes face complex metabolic challenges that are not addressed by insulin therapy alone. In fact, insulin induces downstream metabolic effects such as insulin resistance and weight gain. Adjunctive therapies are increasingly used off-label to manage these metabolic challenges. This presentation will discuss the state of evidence for adjunctive therapies in type 1 diabetes, practical prescribing guidance, evidence gaps and future research directions.

Authors contributing to this presentation.

Snaith, J

Dr Jennifer Snaith is Post-doctoral Scientist at the Victor Chang Cardiac Research Institute and Staff Specialist Endocrinologist who leads the Diabetes in Youth service at St Vincent’s Hospital, Sydney. She is group co-lead of the Australian Collaborative Towards Adjunctive Therapies in Type 1 Diabetes (ACT-T1D). Her research interest is the intersection between type 1 diabetes, metabolic and cardiovascular health, and the role of adjunctive therapies in type 1 diabetes. Active or completed trials include the INTIMET study (metformin), RESET1 (semaglutide), TIRTLE1 (tirzepatide) and TIRTLE2 (tirzepatide).

Adjunctive therapies in type 1 diabetes: What, when and for whom? (149953)

Add notes

Snaith, J

Login